Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
The First Agentic Operating System for Life Sciences R&D PRESS RELEASE Already running NVIDIA BioNeMo in production, the SigmaticOS now leverages NVIDIA’s latest agentic innovations to connect...
-
This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in EoETopline results for the double-blind 12-week treatment portion of the study are expected in Q4...
-
VERAXA Biotech AG (NASDAQ: VRXA) has generated new in vitro proof-of-concept data validating its novel BiTAC-ADC technology platform.
-
Intravacc and Primrose Bio Renew Partnership to Enhance Conjugate Vaccine Development.
-
Intravacc and Primrose Bio Renew Partnership to Enhance Conjugate Vaccine Development.
-
The 2025-2027 approval helps French innovators access Intravacc’s vaccine development, analytical development and cGMP manufacturing services.
-
The 2025-2027 approval helps French innovators access Intravacc’s vaccine development, analytical development and cGMP manufacturing services.
-
Valable pour la période 2025–2027, cet agrément permet aux entreprises innovantes françaises de faire appel à l’expertise d’Intravacc dans le développement de vaccins, le développement analytique et...
-
Die Zulassung für den Zeitraum 2025–2027 ermöglicht französischen Innovatoren den Zugang zu den Dienstleistungen von Intravacc in den Bereichen Impfstoffentwicklung, analytische Entwicklung und...
-
On May 8, 2026, 3E Network obtained $1.3M funding and established Chip Business Unit to develop semiconductor and AI compute infrastructure.